Humana (NYSE:HUM) Price Target Raised to $316.00

Humana (NYSE:HUM - Free Report) had its price objective raised by Mizuho from $305.00 to $316.00 in a research note released on Wednesday,Benzinga reports. Mizuho currently has an outperform rating on the insurance provider's stock.

HUM has been the topic of several other research reports. StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a research report on Monday, April 7th. Piper Sandler raised their target price on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 15th. Barclays lifted their target price on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Royal Bank of Canada restated an "outperform" rating and issued a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Finally, Morgan Stanley reduced their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Seventeen investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $288.60.

Remove Ads

Humana Stock Performance

Shares of HUM traded down $11.29 during mid-day trading on Wednesday, hitting $283.75. The stock had a trading volume of 610,398 shares, compared to its average volume of 1,747,807. Humana has a 52 week low of $213.31 and a 52 week high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The business has a fifty day moving average price of $265.55 and a 200-day moving average price of $270.35. The firm has a market cap of $34.25 billion, a P/E ratio of 28.52, a PEG ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities research analysts expect that Humana will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Friday, March 28th. Humana's payout ratio is presently 35.58%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. FPC Investment Advisory Inc. bought a new stake in Humana in the 4th quarter worth $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana in the 4th quarter worth approximately $30,000. LFA Lugano Financial Advisors SA grew its position in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares during the last quarter. Riverview Trust Co bought a new position in shares of Humana during the first quarter valued at approximately $34,000. Finally, OFI Invest Asset Management bought a new position in shares of Humana during the fourth quarter valued at approximately $33,000. 92.38% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.